Table 3. Safety and adverse event analysis in patients with advanced HCC treated with PD-1 inhibitors and regorafenib.

Adverse events	Grade 1, n (%)	Grade 2, n (%)	Grade 3, n (%)
Fatigue	2 (11.76)	1 (5.88)	0
Diarrhea	0	3 (17.65)	0
Hypertension	2 (11.76)	0	0
Bleeding gums	2 (11.76)	0	0
Proteinuria	0	0	1 (5.88)
Red rash	0	1 (5.88)	0
Oral mucositis	0	1 (5.88)	0
Rash	1 (5.88)	0	0
Hand/foot/skin reaction	1 (5.88)	0	0
Hair loss	1 (5.88)	0	0
No appetite	1 (5.88)	0	0
Gastrointestinal bleeding	0	0	1 (5.88)
Peptic ulcer	0	0	1 (5.88)

HCC, hepatocellular carcinoma; PD-1, programmed cell death protein 1.